TORL Biotherapeutics LLC
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2018-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.torlbio.com
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
- Conditions
- Epithelial Ovarian CancerPrimary PeritonealFallopian Tube CancerEndometrioid Ovarian Cancer
- Interventions
- First Posted Date
- 2024-11-15
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- TORL Biotherapeutics, LLC
- Target Recruit Count
- 230
- Registration Number
- NCT06690775
- Locations
- 🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸Stephenson Cancer Center at the University of Oklahoma, Oklahoma City, Oklahoma, United States
🇺🇸SCRI - Arizona Oncology Associates, PC-HOPE, Tucson, Arizona, United States
A Phase 1, First in Human Study of TORL-4-500 in Patients with Advanced Cancer
- Conditions
- Advanced Solid TumorHepatocellular Carcinoma
- Interventions
- First Posted Date
- 2023-08-22
- Last Posted Date
- 2025-03-04
- Lead Sponsor
- TORL Biotherapeutics, LLC
- Target Recruit Count
- 70
- Registration Number
- NCT06005740
- Locations
- 🇺🇸
Mayo Clinic Phoenix, Phoenix, Arizona, United States
🇺🇸Providence Medical Foundation, Fullerton, California, United States
🇺🇸UCLA - JCCC Clinical Research Unit, Los Angeles, California, United States
First in Human Study of TORL-3-600 in Participants With Advanced Cancer
- First Posted Date
- 2023-07-17
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- TORL Biotherapeutics, LLC
- Target Recruit Count
- 70
- Registration Number
- NCT05948826
- Locations
- 🇺🇸
Providence Medical Foundation, Fullerton, California, United States
🇺🇸Sarah Cannon Research Institute, Denver, Colorado, United States
🇺🇸Fort Wayne Medical Oncology and Hematology Inc., Fort Wayne, Indiana, United States
First in Human Study of TORL-2-307-MAB in Participants With Advanced Cancer
- Conditions
- Gastric CancerAdvanced Solid TumorPancreas CancerGastroesophageal Junction Adenocarcinoma
- Interventions
- First Posted Date
- 2021-12-16
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- TORL Biotherapeutics, LLC
- Target Recruit Count
- 70
- Registration Number
- NCT05159440
- Locations
- 🇺🇸
Providence St. Jude Medical Center, Fullerton, California, United States
🇺🇸Torrance Memorial Medical, Torrance, California, United States
🇺🇸Fort Wayne Medical Oncology and Hematology, Fort Wayne, Indiana, United States
First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer
- Conditions
- Gastric CancerPancreas CancerAdvanced Solid TumorGastroesophageal Junction Adenocarcinoma
- Interventions
- First Posted Date
- 2021-12-14
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- TORL Biotherapeutics, LLC
- Target Recruit Count
- 70
- Registration Number
- NCT05156866
- Locations
- 🇺🇸
Texas Oncology-Austin, Austin, Texas, United States
🇺🇸UCLA - JCCC Clinical Research Unit, Los Angeles, California, United States
🇺🇸Washington University School of Medicine-Siteman Cancer Center, Saint Louis, Missouri, United States
First in Human Study of TORL-1-23 in Participants With Advanced Cancer
- Conditions
- Advanced Solid TumorEndometrial CancerNSCLCOvarian Cancer
- Interventions
- First Posted Date
- 2021-11-02
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- TORL Biotherapeutics, LLC
- Target Recruit Count
- 90
- Registration Number
- NCT05103683
- Locations
- 🇺🇸
Providence Medical Foundation, Fullerton, California, United States
🇺🇸UCLA - JCCC Clinical Research Unit, Los Angeles, California, United States
🇺🇸University of Kentucky Medical Center, Lexington, Kentucky, United States